title: Commentary on "Recombinant Humanized Anti-HER2 Antibody (Herceptin) Enhances the Antitumor Activity of Paclitaxel and Doxorubicin against HER2/neu Overexpressing Human Breast Cancer Xenografts" (A Follow Up).
authors.affiliation: Khalifa Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas. jmendelsohn@mdanderson.org.
authors.forename: John
authors.initials: J
authors.lastname: Mendelsohn
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000266:history* / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000266:history* / Q000473:pathology; D002986:Clinical Trials as Topic / Q000266:history; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D049673:History, 20th Century; D006801:Humans; D051379:Mice; D017239:Paclitaxel / Q000008:administration & dosage; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis; D000068878:Trastuzumab / Q000008:administration & dosage; D023041:Xenograft Model Antitumor Assays
chemical_list: D004317:Doxorubicin; D017239:Paclitaxel; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human